131 related articles for article (PubMed ID: 11474478)
1. Effect of alendronate on bone mineral density in male idiopathic osteoporosis.
Weber TJ; Drezner MK
Metabolism; 2001 Aug; 50(8):912-5. PubMed ID: 11474478
[TBL] [Abstract][Full Text] [Related]
2. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
3. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
4. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study.
Gonnelli S; Cepollaro C; Montagnani A; Bruni D; Caffarelli C; Breschi M; Gennari L; Gennari C; Nuti R
Calcif Tissue Int; 2003 Aug; 73(2):133-9. PubMed ID: 14565594
[TBL] [Abstract][Full Text] [Related]
5. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
Rozenberg S; Lanoy E; Bentata M; Viard JP; Valantin MA; Missy P; Darasteanu I; Roux C; Kolta S; Costagliola D;
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):972-80. PubMed ID: 22353022
[TBL] [Abstract][Full Text] [Related]
6. Alendronate for the treatment of osteoporosis in men.
Orwoll E; Ettinger M; Weiss S; Miller P; Kendler D; Graham J; Adami S; Weber K; Lorenc R; Pietschmann P; Vandormael K; Lombardi A
N Engl J Med; 2000 Aug; 343(9):604-10. PubMed ID: 10979796
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
8. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.
Ringe JD; Dorst A; Farahmand P
Arzneimittelforschung; 2010; 60(5):267-72. PubMed ID: 20533764
[TBL] [Abstract][Full Text] [Related]
10. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
11. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
12. [Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture].
Qiu GX; Wu ZH; Shen JX; Luo XZ; Tang H; Wang YP; Weng XS; Yang XY; Lin J; Jin J; Zhao H; Tian Y; Zhang JG
Zhonghua Wai Ke Za Zhi; 2004 Mar; 42(6):347-50. PubMed ID: 15144688
[TBL] [Abstract][Full Text] [Related]
13. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
14. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
15. Effects of alendronate on bone density in men with primary and secondary osteoporosis.
Ho YV; Frauman AG; Thomson W; Seeman E
Osteoporos Int; 2000; 11(2):98-101. PubMed ID: 10793867
[TBL] [Abstract][Full Text] [Related]
16. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
[TBL] [Abstract][Full Text] [Related]
17. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.
Uchida K; Nakajima H; Miyazaki T; Yayama T; Kawahara H; Kobayashi S; Tsuchida T; Okazawa H; Fujibayashi Y; Baba H
J Nucl Med; 2009 Nov; 50(11):1808-14. PubMed ID: 19837766
[TBL] [Abstract][Full Text] [Related]
18. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
19. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Vis M; Bultink IE; Dijkmans BA; Lems WF
Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]